No Acute Effects of Exogenous Glucose-Dependent Insulinotropic Polypeptide on Energy Intake, Appetite, or Energy Expenditure When Added to Treatment With a Long-Acting Glucagon-Like Peptide 1 Receptor Agonist in Men With Type 2 Diabetes
The DOI matches its Crossref record; 42 of the 43 references it cites were found in a registry or an index.
Abstract
OBJECTIVE: Dual incretin receptor agonists in clinical development have shown reductions in body weight and hemoglobin A1c (HbA1c) in patients with type 2 diabetes, but the impact of glucose-dependent insulinotropic polypeptide (GIP) receptor activation remains unclear. Here, we evaluated the effects of high-dose exogenous GIP on energy intake, energy expenditure, plasma glucose, and glucose-regulating hormones in patients with type 2 diabetes treated with a long-acting glucagon-like peptide 1 receptor (GLP-1R) agonist. RESEARCH DESIGN AND METHODS: In a randomized, double-blind design, men with type 2 diabetes (n = 22, mean ± SEM HbA1c 6.8 ± 0.1% [51 ± 1.5 mmol/mol]) treated with metformin and long-acting GLP-1R agonists were subjected to two 5-h continuous infusions (separated by a washout period of ≥3 days): one with GIP (6 pmol/kg/min) and another with saline (placebo). After 60 min of infusion, a liquid mixed-meal test was performed, and after 270 min of infusion, an ad libitum meal was served for evaluation of energy intake (primary end point). RESULTS: Energy intake was similar during GIP and placebo infusion (648 ± 74 kcal vs. 594 ± 55 kcal, respectively; P = 0.480), as were appetite measures and energy expenditure. Plasma glucagon and glucose were higher during GIP infusion compared with placebo infusion (P = 0.026 and P = 0.017) as assessed by area under the curve. CONCLUSIONS: In patients with type 2 diabetes, GIP infusion on top of treatment with metformin and a long-acting GLP-1R agonist did not affect energy intake, appetite, or energy expenditure but increased plasma glucose compared with placebo. These results indicate no acute beneficial effects of combining GIP and GLP-1.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“despite that this additive effect in food intake and glycaemia was not observed in some acute clinical studies [41, 42].”
From What is the pipeline for future medications for obesity? (2025) · cites this paper as [41]
Citations
Cites
Controlling the False Discovery Rate: A Practical and Powerful Approach to Multiple Testing
Benjamini, Y., & Hochberg, Y. (1995) · Journal of the Royal Statistical Society Series B: Statistical Methodology · doi:10.1111/j.2517-6161.1995.tb02031.x · Cited by 109,482 · cited 2×
“P values were corrected for multiple testing using the Benjamini-Hochberg procedure (31).”
MethodAdjusting batch effects in microarray expression data using empirical Bayes methods
Johnson, W. E., Li, C., & Rabinovic, A. (2007) · Biostatistics · doi:10.1093/biostatistics/kxj037 · Cited by 8,658
Nauck, M. A., Heimesaat, M. M., Orskov, C., Holst, J. J., Ebert, R., & Creutzfeldt, W. (1993) · Journal of Clinical Investigation · doi:10.1172/jci116186 · Cited by 1,651 · cited 2×
“Infusions Synthetic human GIP (1-42) (;96% purity) was purchased from Bachem care.”
BackgroundMethodSelf-citationGlucagon-like peptide 1 promotes satiety and suppresses energy intake in humans.
Flint, A., Raben, A., Astrup, A., & Holst, J. J. (1998) · Journal of Clinical Investigation · doi:10.1172/jci990 · Cited by 1,402 · cited 2×
“GLP-1 furthermoreacts as a satiety-promoting hormone (4), and GLP-1 receptor (GLP-1R) agonists with plasmaglucose–loweringandbodyweight– reducing effects have been developed for thetreatmentof type2diabetesandobesity.”
BackgroundMethodSelf-citationInhibition of gastric inhibitory polypeptide signaling prevents obesity
Miyawaki, K., Yamada, Y., Ban, N., Ihara, Y., Tsukiyama, K., Zhou, H., Fujimoto, S., Oku, A., Tsuda, K., Toyokuni, S., et al. (2002) · Nature Medicine · doi:10.1038/nm727 · Cited by 963
Self-citationTissue and Plasma Concentrations of Amidated and Glycine-Extended Glucagon-Like Peptide I in Humans
Ørskov, C., Rabenhøj, L., Wettergren, A., Kofod, H., & Holst, J. J. (1994) · Diabetes · doi:10.2337/diab.43.4.535 · Cited by 919 · cited 1×
“Infusions Synthetic human GIP (1-42) (;96% purity) was purchased from Bachem care.”
MethodSelf-citationCoskun, T., Sloop, K. W., Loghin, C., Alsina-Fernandez, J., Urva, S., Bokvist, K. B., Cui, X., Briere, D. A., Cabrera, O., Roell, W. C., et al. (2018) · Molecular Metabolism · doi:10.1016/j.molmet.2018.09.009 · Cited by 882
NAUCK, M. A., HOMBERGER, E., SIEGEL, E. G., ALLEN, R. C., EATON, R. P., EBERT, R., & CREUTZFELDT, W. (1986) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem-63-2-492 · Cited by 874 · cited 1×
“Infusions Synthetic human GIP (1-42) (;96% purity) was purchased from Bachem care.”
MethodFrias, J. P., Nauck, M. A., Van, J., Kutner, M. E., Cui, X., Benson, C., Urva, S., Gimeno, R. E., Milicevic, Z., Robins, D., et al. (2018) · The Lancet · doi:10.1016/s0140-6736(18)32260-8 · Cited by 815
Unimolecular Dual Incretins Maximize Metabolic Benefits in Rodents, Monkeys, and Humans
Finan, B., Ma, T., Ottaway, N., Müller, T. D., Habegger, K. M., Heppner, K. M., Kirchner, H., Holland, J., Hembree, J., Raver, C., et al. (2013) · Science Translational Medicine · doi:10.1126/scitranslmed.3007218 · Cited by 696
T., V., T., K., S., M., & J., H. (2002) · Diabetologia · doi:10.1007/s00125-002-0878-6 · Cited by 518 · cited 2×
“Infusions Synthetic human GIP (1-42) (;96% purity) was purchased from Bachem care.”
BackgroundMethodNauck, M. A. (1993) · Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.76.4.912 · Cited by 506 · cited 1×
“Infusions Synthetic human GIP (1-42) (;96% purity) was purchased from Bachem care.”
MethodHøjberg, P. V., Vilsbøll, T., Rabøl, R., Knop, F. K., Bache, M., Krarup, T., Holst, J. J., & Madsbad, S. (2009) · Diabetologia · doi:10.1007/s00125-008-1195-5 · Cited by 414 · cited 3×
“Infusions Synthetic human GIP (1-42) (;96% purity) was purchased from Bachem care.”
BackgroundMethodSelf-citationFrias, J. P., Bastyr, E. J., Vignati, L., Tschöp, M. H., Schmitt, C., Owen, K., Christensen, R. H., & DiMarchi, R. D. (2017) · Cell Metabolism · doi:10.1016/j.cmet.2017.07.011 · Cited by 321 · cited 2×
“Infusions Synthetic human GIP (1-42) (;96% purity) was purchased from Bachem care.”
BackgroundMethodSonographic measurement of gallbladder volume
Dodds, W., Groh, W., Darweesh, R., Lawson, T., Kishk, S., & Kern, M. (1985) · American Journal of Roentgenology · doi:10.2214/ajr.145.5.1009 · Cited by 320 · cited 2×
“Infusions Synthetic human GIP (1-42) (;96% purity) was purchased from Bachem care.”
MethodElahi, D., McAloon-Dyke, M., Fukagawa, N. K., Meneilly, G. S., Sclater, A. L., Minaker, K. L., Habener, J. F., & Andersen, D. K. (1994) · Regulatory Peptides · doi:10.1016/0167-0115(94)90136-8 · Cited by 309
Optimized GIP analogs promote body weight lowering in mice through GIPR agonism not antagonism
Mroz, P. A., Finan, B., Gelfanov, V., Yang, B., Tschöp, M. H., DiMarchi, R. D., & Perez-Tilve, D. (2019) · Molecular Metabolism · doi:10.1016/j.molmet.2018.12.001 · Cited by 229
Mentis, N., Vardarli, I., Köthe, L. D., Holst, J. J., Deacon, C. F., Theodorakis, M., Meier, J. J., & Nauck, M. A. (2011) · Diabetes · doi:10.2337/db10-1332 · Cited by 197
Self-citationGasbjerg, L. S., Helsted, M. M., Hartmann, B., Jensen, M. H., Gabe, M. B. N., Sparre-Ulrich, A. H., Veedfald, S., Stensen, S., Lanng, A. R., Bergmann, N. C., et al. (2019) · Diabetes · doi:10.2337/db18-1123 · Cited by 193
Self-citationIncretin Hormone and Insulin Responses to Oral Versus Intravenous Lipid Administration in Humans
Lindgren, O., Carr, R. D., Deacon, C. F., Holst, J. J., Pacini, G., Mari, A., & Ahrén, B. (2011) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2011-0266 · Cited by 188 · cited 1×
“Infusions Synthetic human GIP (1-42) (;96% purity) was purchased from Bachem care.”
MethodSelf-citationKim, S.-J., Nian, C., Karunakaran, S., Clee, S. M., Isales, C. M., & McIntosh, C. H. S. (2012) · PLoS ONE · doi:10.1371/journal.pone.0040156 · Cited by 182
Reappraisal of GIP Pharmacology for Metabolic Diseases
Finan, B., Müller, T. D., Clemmensen, C., Perez-Tilve, D., DiMarchi, R. D., & Tschöp, M. H. (2016) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2016.03.005 · Cited by 180
ISEC: a program to calculate insulin secretion
Hovorka, R., Soons, P. A., & Young, M. A. (1996) · Computer Methods and Programs in Biomedicine · doi:10.1016/0169-2607(96)01755-5 · Cited by 177 · cited 2×
“Infusions Synthetic human GIP (1-42) (;96% purity) was purchased from Bachem care.”
MethodChia, C. W., Carlson, O. D., Kim, W., Shin, Y.-K., Charles, C. P., Kim, H. S., Melvin, D. L., & Egan, J. M. (2009) · Diabetes · doi:10.2337/db08-0958 · Cited by 176 · cited 2×
“Infusions Synthetic human GIP (1-42) (;96% purity) was purchased from Bachem care.”
BackgroundMethodLund, A., Vilsbøll, T., Bagger, J. I., Holst, J. J., & Knop, F. K. (2011) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00665.2010 · Cited by 170
Self-citationEvidence of Extrapancreatic Glucagon Secretion in Man
Lund, A., Bagger, J. I., Wewer Albrechtsen, N. J., Christensen, M., Grøndahl, M., Hartmann, B., Mathiesen, E. R., Hansen, C. P., Storkholm, J. H., van Hall, G., et al. (2016) · Diabetes · doi:10.2337/db15-1541 · Cited by 168 · cited 1×
“Infusions Synthetic human GIP (1-42) (;96% purity) was purchased from Bachem care.”
MethodSelf-citationBergmann, N. C., Lund, A., Gasbjerg, L. S., Meessen, E. C. E., Andersen, M. M., Bergmann, S., Hartmann, B., Holst, J. J., Jessen, L., Christensen, M. B., et al. (2019) · Diabetologia · doi:10.1007/s00125-018-4810-0 · Cited by 142 · cited 4×
“Also, GIP infusion does not result in a reduction in energy intake or increase in energy expenditure, whichwould indicate a later bodyweight loss (19,20).”
BackgroundMethodInfluentialSelf-citationVaccination against GIP for the Treatment of Obesity
Fulurija, A., Lutz, T. A., Sladko, K., Osto, M., Wielinga, P. Y., Bachmann, M. F., & Saudan, P. (2008) · PLoS ONE · doi:10.1371/journal.pone.0003163 · Cited by 136 · cited 1×
“Infusions Synthetic human GIP (1-42) (;96% purity) was purchased from Bachem care.”
MethodLet's stay together: Towards traffic aware virtual machine placement in data centers
Li, X., Wu, J., Tang, S., & Lu, S. (2014) · IEEE INFOCOM 2014 - IEEE Conference on Computer Communications · doi:10.1109/infocom.2014.6848123 · Cited by 128
Gault, V. A., Kerr, B. D., Harriott, P., & Flatt, P. R. (2011) · Clinical Science · doi:10.1042/cs20110006 · Cited by 125 · cited 2×
“Infusions Synthetic human GIP (1-42) (;96% purity) was purchased from Bachem care.”
MethodResultNørregaard, P. K., Deryabina, M. A., Tofteng Shelton, P., Fog, J. U., Daugaard, J. R., Eriksson, P., Larsen, L. F., & Jessen, L. (2018) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.13034 · Cited by 116 · cited 2×
“Infusions Synthetic human GIP (1-42) (;96% purity) was purchased from Bachem care.”
MethodResultSelf-citationChristensen, M. B., Calanna, S., Holst, J. J., Vilsbøll, T., & Knop, F. K. (2014) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2013-3644 · Cited by 99 · cited 2×
“Infusions Synthetic human GIP (1-42) (;96% purity) was purchased from Bachem care.”
BackgroundMethodSelf-citationKnop, F. K., Vilsbøll, T., Højberg, P. V., Larsen, S., Madsbad, S., Holst, J. J., & Krarup, T. (2007) · Regulatory Peptides · doi:10.1016/j.regpep.2007.07.002 · Cited by 73
Self-citationChristensen, M., Sparre‐Ulrich, A. H., Hartmann, B., Grevstad, U., ROSENKILDE, M. M., Holst, J. J., Vilsbøll, T., & Knop, F. K. (2015) · International Journal of Obesity · doi:10.1038/ijo.2015.136 · Cited by 71 · cited 2×
“Infusions Synthetic human GIP (1-42) (;96% purity) was purchased from Bachem care.”
MethodSelf-citationGastric inhibitory polypeptide immunoneutralization attenuates development of obesity in mice
Boylan, M. O., Glazebrook, P. A., Tatalovic, M., & Wolfe, M. M. (2015) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00345.2015 · Cited by 65 · cited 1×
“Infusions Synthetic human GIP (1-42) (;96% purity) was purchased from Bachem care.”
MethodDaousi, C., Wilding, J. P. H., Aditya, S., Durham, B. H., Cleator, J., Pinkney, J. H., & Ranganath, L. R. (2009) · Clinical Endocrinology · doi:10.1111/j.1365-2265.2008.03451.x · Cited by 65 · cited 2×
“Also, GIP infusion does not result in a reduction in energy intake or increase in energy expenditure, whichwould indicate a later bodyweight loss (19,20).”
BackgroundMethodAsmar, M., Simonsen, L., Arngrim, N., Holst, J. J., Dela, F., & Bülow, J. (2013) · International Journal of Obesity · doi:10.1038/ijo.2013.73 · Cited by 57
Self-citationNexøe‐Larsen, C. C., Sørensen, P. H., Hausner, H., Agersnap, M., Baekdal, M., Brønden, A., Gustafsson, L. N., Sonne, D. P., Vedtofte, L., Vilsbøll, T., et al. (2018) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.13420 · Cited by 51 · cited 2×
“Infusions Synthetic human GIP (1-42) (;96% purity) was purchased from Bachem care.”
MethodSelf-citationAaboe, K., Akram, S., Deacon, C. F., Holst, J. J., Madsbad, S., & Krarup, T. (2015) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12395 · Cited by 48 · cited 2×
“Infusions Synthetic human GIP (1-42) (;96% purity) was purchased from Bachem care.”
BackgroundMethodSelf-citationAsmar, M., Arngrim, N., Simonsen, L., Asmar, A., Nordby, P., Holst, J. J., & Bülow, J. (2016) · Nutrition & Diabetes · doi:10.1038/nutd.2016.15 · Cited by 42 · cited 2×
“with lean individuals but seems to be somewhat restored followingweight loss (35,36).”
BackgroundMethodSelf-citationLee, M. Y., Fraser, J. D., Chapman, M. J., Sundararajan, K., Umapathysivam, M. M., Summers, M. J., Zaknic, A. V., Rayner, C. K., Meier, J. J., Horowitz, M., et al. (2013) · Diabetes Care · doi:10.2337/dc13-0307 · Cited by 23 · cited 1×
“Infusions Synthetic human GIP (1-42) (;96% purity) was purchased from Bachem care.”
Method“Let's Stay Together”; GIP and GLP-1 dual agonism in the treatment of metabolic disease
DiMarchi, R. D. (2018) · Molecular Metabolism · doi:10.1016/j.molmet.2018.10.004 · Cited by 8 · cited 2×
“Thus, a renewed interest in GIPR agonism as a potentially effective add-on to GLP-1R agonism in type2diabeteshasbeen introduced, but thecontributionofGIPRactivation to the results obtained with the GIPR/GLP-1R dual agonists remains uncertain in humans (5,26).”
BackgroundMethod
Cited by
Tirzepatide is an imbalanced and biased dual GIP and GLP-1 receptor agonist
Willard, F. S., Douros, J. D., Gabe, M. B. N., Showalter, A. D., Wainscott, D. B., Suter, T. M., Capozzi, M. E., van der Velden, W. J. C., Stutsman, C., Cardona, G. R., et al. (2020) · JCI Insight · doi:10.1172/jci.insight.140532 · Cited by 541
Self-citationWhat is the pipeline for future medications for obesity?
Melson, E., Ashraf, U., Papamargaritis, D., & Davies, M. J. (2025) · International Journal of Obesity · doi:10.1038/s41366-024-01473-y · Cited by 332
“…WL and glucose-lowering ef fi cacy compared to activation of each receptor alone [38 – 40], the interest for the development of unimolecular GLP-1 and GIP RA was increased, despite that this additive effect in food intake and glycaemia was not observed in some acute clinical studies [41, 42].”
Mechanisms of action and therapeutic applications of GLP-1 and dual GIP/GLP-1 receptor agonists
Liu, Q. K. (2024) · Frontiers in Endocrinology · doi:10.3389/fendo.2024.1431292 · Cited by 265
The expanding incretin universe: from basic biology to clinical translation
Drucker, D. J., & Holst, J. J. (2023) · Diabetologia · doi:10.1007/s00125-023-05906-7 · Cited by 243
Self-citationGIP as a Therapeutic Target in Diabetes and Obesity: Insight From Incretin Co-agonists
Holst, J. J., & Rosenkilde, M. M. (2020) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgaa327 · Cited by 207
“However, the disappointing results of adding high-dose GIP infusions to chronic liraglutide treatment (31) speak against this possibility.”
BackgroundSelf-citation
Metadata
- Authors
- Bergmann, N. C., Gasbjerg, L. S., Heimbürger, S. M., Krogh, L. S. L., Dela, F., Hartmann, B., Holst, J. J., Jessen, L., Christensen, M. B., Vilsbøll, T., Lund, A., & Knop, F. K.
- Affiliations
- University of Copenhagen (DK)
- Zealand Pharma (Denmark) (DK)
- Corresponding author
- Knop, Filip K.
- ORCID
- Venue
- Diabetes Care
- Publisher
- American Diabetes Association
- Published
- 2020-01-16
- Volume
- 43
- Issue
- 3
- Pages
- 588-596
- ISSN
- 0149-5992 (ISSN-L)
- 1935-5548
- OpenAlex
- W3000683010
- Cited by
- 62
- References
- 43
- Citations by year
- 2026: 3 · 2025: 9 · 2024: 13 · 2023: 12 · 2022: 8 · 2021: 9 · 2020: 7
- FWCI
- 6.79
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Diabetes Care (publishedVersion)
- PubMed (publishedVersion)
- Research at the University of Copenhagen (University of Copenhagen) (submittedVersion)
- Funders
- Innovation Fund Denmark
- A.P. Møller Foundation
- Aase and Ejnar Danielsens Foundation
- Danish Medical Research Grant
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Life Sciences › Neuroscience › Endocrine and Autonomic Systems › Regulation of Appetite and Obesity
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Keywords
- glucose-dependent insulinotropic polypeptide, GIP receptor agonist, GLP-1 receptor agonists, type 2 diabetes, energy intake, appetite, energy expenditure, metformin, plasma glucagon, plasma glucose, mixed meal tolerance test
- MeSH terms
- Glucagon-Like Peptide-1 Receptor Agonists, Adult, Aged, Appetite, Energy Intake, Delayed-Action Preparations, Diabetes Mellitus, Type 2, Double-Blind Method, Drug Administration Schedule, Drug Therapy, Combination, Energy Metabolism, Gastric Inhibitory Polypeptide, Glucagon, Glycated Hemoglobin, Humans, Insulin, Male, Middle Aged, Glucagon-Like Peptide 1
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.